shared knowledge shared progress

Related News

Lhasa Limited continues to support the global challenge of nitrosamine impurity assessment
With 164 new nitrite results, bringing the total number to 440 nitrite results for 64 common excipients, Lhasa Limited is pleased to announce the release of the 2021.1 Nitrites in Excipients database.
05 March 2021
Lhasa Limited releases new data to its Nitrites in Excipients project users
15 December 2020
Lhasa Limited releases new data to its Aromatic Amines project users
26 November 2020

Recent News

Lhasa Limited continues to support the global challenge of nitrosamine impurity assessment
With 164 new nitrite results, bringing the total number to 440 nitrite results for 64 common excipients, Lhasa Limited is pleased to announce the release of the 2021.1 Nitrites in Excipients database.
05 March 2021

Recent Blog Articles

How to better anticipate and mitigate adverse drug reactions [an infographic]
Are you interested in using your data to anticipate and mitigate adverse drug reactions? The Effiris consortium - currently composed of Takeda, GSK and UCB - is working to achieve just that.
17 February 2021

Upcoming Events

Virtual Conference: 2021 Society of Toxicology (SOT) Annual Meeting

Mar 15 2021
Virtual Conference: 2021 BTS Annual Congress

Apr 12 2021
Virtual Conference: 2021 International Akademie Fresenius Conference | QSAR and Read-Across in Toxicological Assessments

Apr 28 2021

Recent News

Lhasa Limited continues to support the global challenge of nitrosamine impurity assessment
With 164 new nitrite results, bringing the total number to 440 nitrite results for 64 common excipients, Lhasa Limited is pleased to announce the release of the 2021.1 Nitrites in Excipients database.
05 March 2021
Lhasa Limited releases new data to its Nitrites in Excipients project users
15 December 2020
Lhasa Limited releases new data to its Aromatic Amines project users
26 November 2020

Recent Blog Articles

How to better anticipate and mitigate adverse drug reactions [an infographic]
Are you interested in using your data to anticipate and mitigate adverse drug reactions? The Effiris consortium - currently composed of Takeda, GSK and UCB - is working to achieve just that.
17 February 2021
Working together to address the potential presence of nitrosamine impurities in medications
25 January 2021
How Human Resources can positively influence a changing work environment.
18 January 2021

Archive

This is a library of Lhasa's blog articles.

5 minutes
Lhasa Limited supports an international initiative in the fight against COVID-19
Coronaviruses are a large family of viruses which can affect humans or other species and can range anywhere from a mild illness such as the common cold to more severe illnesses such as Severe Acute Respiratory Syndrome (SARS). Coronavirus disease 2019 (COVID-19) is an infectious disease caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
- Innovation
- Initiatives
25 June 2020

Sitemap

© 2021 Lhasa Limited | Registered office: Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK Tel: +44 (0)113 394 6020
VAT number 396 8737 77 | Lhasa Limited is registered as a charity (290866)| Company Registration Number 01765239 (England and Wales).

Apart from the free survey software, we also have access to QuestionPro's free survey templates . We've found many of them useful and powerful to collect insights from various stakeholders of our organization.

Related News

Lhasa Limited continues to support the global challenge of nitrosamine impurity assessment

Lhasa Limited releases new data to its Nitrites in Excipients project users

Lhasa Limited releases new data to its Aromatic Amines project users

Related Blog Articles

Working together to address the potential presence of nitrosamine impurities in medications

Lhasa Limited supports the global challenge of nitrosamine impurity assessment

The Importance of Pre-competitive Collaborations

Recent News

Lhasa Limited continues to support the global challenge of nitrosamine impurity assessment

Recent Blog Articles

How to better anticipate and mitigate adverse drug reactions [an infographic]

Recent Publications

Case study on the use of integrated approaches to testing and assessment for the prediction of a 90-day repeated dose toxicity study (OECD 408) for 2-Ethylbutyric acid using a read-across approach from other branched carboxylic acids.

Guidelines for FAIR sharing of preclinical safety and off-target pharmacology data

2021 Webinar - An overview of Effiris 2.1; An enhanced qualitative model suite for anticipating and mitigating adverse drug reactions – Slides and recording

Upcoming Events

Virtual Conference: 2021 Society of Toxicology (SOT) Annual Meeting

Virtual Conference: 2021 BTS Annual Congress

Virtual Conference: 2021 International Akademie Fresenius Conference | QSAR and Read-Across in Toxicological Assessments

Recent News

Lhasa Limited continues to support the global challenge of nitrosamine impurity assessment

Lhasa Limited releases new data to its Nitrites in Excipients project users

Lhasa Limited releases new data to its Aromatic Amines project users

Recent Blog Articles

How to better anticipate and mitigate adverse drug reactions [an infographic]

Working together to address the potential presence of nitrosamine impurities in medications

How Human Resources can positively influence a changing work environment.

Archive

Filter by Category

Filter by Author

Filter by Product

Lhasa Limited supports an international initiative in the fight against COVID-19